Leqembi won accelerated approval by the FDA in January based on its ability to remove sticky amyloid plaques from the brain. The panel on Friday considered Eisai's large confirmatory trial designed to show the drug benefited patients.
from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/bSTENyi
Home »
Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com
» US FDA panel backs approval for Eisai-Biogen Alzheimer's drug Leqembi
https://ift.tt/fRlqvFH
No comments:
Post a Comment